Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer
Lymphoma
Sponsor
Pharmacyclics
Protocol Number
PCYC-1145-LT
To Learn More Call
201-510-0910
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Acerta
Protocol Number
Acerta ACE-LY-308
To Learn More Call
201-510-0910
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Type of Cancer
Lymphoma
Sponsor
TG Therapeutics
Protocol Number
TGR 1202-201
To Learn More Call
201-510-0910
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Type of Cancer
Lymphoma
Site
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN35-015
To Learn More Call
201-510-0910
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Type of Cancer
Lymphoma
Site
Hackensack
Sponsor
Hackensack UMC
Protocol Number
Hakcensack UMC 10R22
To Learn More Call
201-510-0910
HUMAN BIOLOGICAL MATERIAL RESEARCH
Sponsor
University of Nebraska
Protocol Number
Pro2016-0163
To Learn More Call
201-510-0910
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)
Type of Cancer
Lymphoma
Site
East Brunswick, Howell
Protocol Number
INCB 50465-202
To Learn More Call
201-510-0910
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR 1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Sponsor
TG Therapeutics
Protocol Number
UTX-TGR-205
To Learn More Call
201-510-0910
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Type of Cancer
Lymphoma
Site
Howell
Protocol Number
INCB 50465-102
To Learn More Call
201-510-0910
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Type of Cancer